Loading company
GridAI Technologies Corp.
GRDX · Nasdaq · ·
$3.30-5.2%Sep 29 close
- 1M
- -16.7%
- 6M
- +64.2%
- 1Y
- -34.0%
GRDX · Nasdaq · ·
$3.30-5.2%Sep 29 close
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Profit | -$13M | -$998.3K | -1,206.29% |
| Profit per share | -$2.01 | -$0.23 | -773.91% |
| Free Cash Flow | -$5.9M | -$5.9M | +0.52% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
GridAI Technologies Corp. has no earnings call transcript available.
OPTION trial is a Phase II, open-label, multicenter, 2x2 crossover study assessing the safety and efficacy of MS1819-SD versus porcine PERT given at the same dose that was being administered during the pre-study period. Approximately 30 evaluable patients will complete both crossover periods. The primary efficacy endpoint will be a comparison of CFAs after each of the two crossover periods.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from GridAI Technologies Corp.’s Item 2.02 8-K filed December 20, 2018; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.